Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 161

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Topotecan Compared With No Therapy After Response to Surgery and Carboplatin/Paclitaxel in Patients With Ovarian Cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) Randomized Study

Open access
De Placido, Sabino, Scambia, Giovanni, Di Vagno, Giovanni, Naglieri, Emanuele, Lombardi, Alessandra Vernaglia, Biamonte, Rosalbino, Marinaccio, Marco, Cartenì, Giacomo, Manzione, Luigi, Febbraro, Antonio, de Matteis, Andrea, Gasparini, Gianpietro, Valerio, Maria Rosaria, Danese, Saverio, Perrone, Francesco, Lauria, Rossella, De Laurentiis, Michele, Greggi, Stefano, Gallo, Ciro, Pignata, Sandro · 2004 · Journal of Clinical Oncology

Abstract

Purpose: Topotecan is an active second-line treatment for advanced ovarian cancer. Its efficacy as consolidation treatment after first-line standard chemotherapy is unknown. Patients and Methods: To investigate whether topotecan (1.5 mg/m 2 on days 1 through 5, four cycles, every 3 weeks) prolonged progression-free survival (PFS) for patients responding to standard carboplatin (area under the curve 5) and paclitaxel (175 mg/m 2 administered as a 3-hour infusion in six cycles; CP), a multicenter phase III study was performed with an 80% power to detect a 50% prolongation of median PFS. Patients were registered at diagnosis and randomized after the end of CP. Results: Two hundred seventy-three patients were randomly assigned (topotecan, n = 137; observation, n = 136), with a median age of 56 years. Stage at diagnosis was advanced in three fourths of patients (stage III in 65% of patients; stage IV in 10%); after primary surgery, 46% had no residual disease and 20% were optimally debulked. After CP, 87% reached a clinical complete response, and 13% achieved a partial response. Neutropenia (grade 3/4 in 58% of the patients) and thrombocytopenia (grade 3 in 21%; grade 4 in 3%) were the most frequent toxicities attributed to topotecan. There was no statistically significant difference in PFS between the arms (P = .83; log-rank test): median PFS was 18.2 months in the topotecan arm and 28.4 in the control arm. Hazard ratio of progression for patients receiving topotecan was 1.18 (95% CI, 0.86 to 1.63) after adjustment for residual disease, interval debulking surgery, and response to CP. Conclusion: The present analysis indicates that consolidation with topotecan does not improve PFS for patients with advanced ovarian cancer who respond to initial chemotherapy with carboplatin and paclitaxel.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2004.09.088

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 161

Metadata

Authors
De Placido, S., Scambia, G., Di Vagno, G., Naglieri, E., Lombardi, A. V., Biamonte, R., Marinaccio, M., Cartenì, G., Manzione, L., Febbraro, A., de Matteis, A., Gasparini, G., Valerio, M. R., Danese, S., Perrone, F., Lauria, R., De Laurentiis, M., Greggi, S., Gallo, C., & Pignata, S.
Venue
Journal of Clinical Oncology
Published
2004-07-01
Volume
22
Issue
13
Pages
2635-2642
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2103194390
Cited by
161
References
1
FWCI
12.48
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Topotecan Compared With No Therapy After Response to Surgery and Carboplatin/Paclitaxel in Patients With Ovarian Cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) Randomized Study. https://app.cochat.ai/papers/10.1200/jco.2004.09.088
The paper
De Placido, S., Scambia, G., Di Vagno, G., Naglieri, E., Lombardi, A. V., Biamonte, R., Marinaccio, M., Cartenì, G., Manzione, L., Febbraro, A., de Matteis, A., Gasparini, G., Valerio, M. R., Danese, S., Perrone, F., Lauria, R., De Laurentiis, M., Greggi, S., Gallo, C., & Pignata, S. (2004). Topotecan Compared With No Therapy After Response to Surgery and Carboplatin/Paclitaxel in Patients With Ovarian Cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) Randomized Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2004.09.088

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.